QRG Capital Management Inc. Trims Holdings in Boston Scientific Corporation $BSX

QRG Capital Management Inc. decreased its position in Boston Scientific Corporation (NYSE:BSX) by 10.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 163,973 shares of the medical equipment provider’s stock after selling 18,627 shares during the quarter. QRG Capital Management Inc.’s holdings in Boston Scientific were worth $16,009,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Steph & Co. bought a new position in Boston Scientific in the 3rd quarter worth about $25,000. Financial Consulate Inc. bought a new position in Boston Scientific in the 3rd quarter worth approximately $25,000. FWL Investment Management LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at approximately $26,000. Sound Income Strategies LLC raised its stake in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares in the last quarter. Finally, Kilter Group LLC bought a new stake in Boston Scientific during the 2nd quarter valued at $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 93,095 shares of company stock worth $9,305,450 over the last 90 days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

Boston Scientific Price Performance

BSX stock opened at $88.13 on Friday. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. The firm has a 50-day moving average of $96.90 and a two-hundred day moving average of $100.32. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $130.65 billion, a PE ratio of 47.13, a P/E/G ratio of 1.59 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same period last year, the company posted $0.63 earnings per share. The firm’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of research analyst reports. The Goldman Sachs Group reissued a “buy” rating and set a $112.00 price target on shares of Boston Scientific in a report on Friday, January 9th. Oppenheimer dropped their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday. UBS Group reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. Evercore ISI set a $112.00 price objective on Boston Scientific in a research note on Monday, January 5th. Finally, BTIG Research restated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a report on Friday, November 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Boston Scientific currently has an average rating of “Buy” and a consensus price target of $123.89.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.